Please use this identifier to cite or link to this item:
http://ri.uaemex.mx/handle20.500.11799/67425
DC Field | Value | Language |
---|---|---|
dc.creator | LAURA JAIMES AGUIRRE | - |
dc.creator | ENRIQUE MORALES AVILA | - |
dc.creator | BLANCA ELI OCAMPO GARCIA | - |
dc.creator | LUIS ALBERTO MEDINA VELAZQUEZ | - |
dc.creator | GUSTAVO LOPEZ TELLEZ | - |
dc.creator | BRENDA VIANEY GIBBENS BANDALA | - |
dc.creator | BERTHA VANESSA IZQUIERDO SANCHEZ | - |
dc.date | 2017-03-18 | - |
dc.date.accessioned | 2022-04-21T05:16:15Z | - |
dc.date.available | 2022-04-21T05:16:15Z | - |
dc.identifier | http://hdl.handle.net/20.500.11799/67425 | - |
dc.identifier.uri | http://ri.uaemex.mx/handle20.500.11799/67425 | - |
dc.description | A novel targeted drug delivery nanoparticle system based on poly(D,L-lactide-co-glycolide) acid (PLGA) for delivery of doxorubicin (DOX) was developed. DOX-PLGA NPs were obtained by the emulsification-solvent evaporation technique. Then, their surface was modified with poly(L-γ-glutamic acid) (γ-PGA) and finally conjugated to modified folic acid (FA) as a targeting ligand. The surface modification and FA conjugation were followed by UV–Vis and FT-IR spectroscopies. Morphology was observed by TEM/SEM. Particle size, PDI and zeta potential were measured using DLS studies. Encapsulation and loading efficiencies, and DOX release kinetics were determined. Specific uptake and cell viability of DOX-PLGA/γ-PGA-FA NPs were tested in HeLa cells. Quasi-spherical nanoparticleswith a particle size lower than 600nm(DLS)were obtained. Spectroscopic techniques demonstrated the successful surface modification with γ-PGA and FA conjugation. Release profile of DOX-PLGA/γ-PGA-FA NPs showed a release of 55.4 ± 0.6% after seven days, in an acidic environment. HeLa cells exhibited a decrease in viability when treated with DOX-PLGA/γ-PGA-AF NPs, and cellular uptake was attributed to FA receptor-mediated endocytosis. These results suggest that DOX-PLGA/γ-PGA-FA NPs are a potential targeted drug carrier for further applications in cancer therapy. | - |
dc.description | This study was supported by the International Atomic Energy Agency (CRP-F22064, Contract No. 18358) and the Universidad Autónoma del Estado de México, through the project No. 3543/2013CHT. | - |
dc.language | eng | - |
dc.publisher | Elsevier, Materials Science and Engineering C | - |
dc.relation | DOI;http://dx.doi.org/10.1016/j.msec.2017.03.145 | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0 | - |
dc.source | 0928-4931 | - |
dc.subject | Folic acid | - |
dc.subject | PLGA nanoparticles | - |
dc.subject | Targeted drug delivery | - |
dc.subject | Multimeric FA nanoparticles | - |
dc.subject | Sustained-release system | - |
dc.subject | info:eu-repo/classification/cti/2 | - |
dc.title | Biodegradable poly(D,L-lactide-co-glycolide)/poly(L-γ-glutamic acid) nanoparticles conjugated to folic acid for targeted delivery of doxorubicin | - |
dc.type | article | - |
dc.audience | students | - |
dc.audience | researchers | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
Appears in Collections: | Producción |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.